BASF, Draws

BASF Draws a Line Under Evonik and Turns the Spotlight on Its Own Pipeline

Published on 11/21/2026 at 09:30 | Editorial boerse-global.de
BASF dropped its Evonik pursuit over price discipline and now must show verifiable milestones for Nemasphere and its methanol cooperation on 24 November.
BASF, Draws, Line, Under, Evonik, Turns, Spotlight, Its, Own, Pipeline Illustration mit AI erstellt.

BASF has made clear that acquisitions are an option within its strategy, not a prerequisite — and the abandoned pursuit of Evonik is the clearest illustration of what that discipline means in practice. The chemicals group saw merit in a tie-up but concluded that Evonik's standalone business prospects and risks did not justify paying more than its final non-binding all-cash offer of 24 euros per share, a package worth roughly 11.2 billion euros.

That distinction — between the value of a deal and the price at which it still makes sense — sits at the heart of the case for BASF shareholders. Chief executive Markus Kamieth argued that a combination could have built a stronger chemicals company, with benefits for shareholders, employees and customers alike. Yet Evonik's management board rejected both non-binding cash offers and, in BASF's reading, showed too little appetite for constructive talks.

RAG-Stiftung Wanted Patience, IG BCE Stayed Wary

Reaction to the collapse came from opposite directions. The RAG-Stiftung, Evonik's largest shareholder, would have liked BASF to show more staying power, a position that became public on Wednesday. The IG BCE trade union struck a more reserved tone. Evonik itself is pinning its future on independent growth.

Price was not the only item on the table. In October 2026 BASF floated possible commitments covering German sites, research and employment through 2032 — concessions under discussion rather than binding pledges. The RAG-Stiftung's appetite for a longer negotiation and Evonik's boardroom rejection are two separate signals; for BASF, the prospect of strategic gain alone was never grounds to raise its bid. Further acquisitions remain within the group's strategy, but in this instance the valuation of Evonik's standalone business settled the question.

Should investors sell immediately? Or is it worth buying BASF?

A Capital Markets Day With Something to Prove

Attention now shifts to 24 November, when BASF holds its capital markets day. The question investors want answered is not whether the company can name more projects, but whether it can show, for those already announced, precisely which steps stand between today and market launch or first revenues. The stock closed Tuesday's session down 2.6% ahead of the event.

Two announcements frame that test. On 16 November BASF said it would advance its Nemasphere soybean technology, with a commercial launch in the US and Brazil targeted for 2028 and peak sales potential put at more than 300 million euros. Separately, a cooperation agreed on Wednesday with DWE on modular plants for sustainable methanol represents, for now, a business opportunity rather than a revenue line.

The gap between launch and peak sales matters for valuation. That 300-million-euro figure describes a potential — it is neither a forecast for the first year nor revenue already booked. Investors would be better served if BASF spelled out the conditions that must be met for commercialisation in both countries and how the business might develop after the planned start, making it easier to judge what the project could contribute and when that contribution would start to count.

Milestones Would Carry More Weight Than Potential

In the best case, BASF would underpin the Nemasphere timetable with verifiable interim steps. A traceable account of the shift from development to marketing would give shareholders more than a long-dated revenue opportunity: they could measure progress against concrete markers without capitalising the full peak figure today. The methanol cooperation faces a different hurdle — the agreement would gain substance if BASF could show how concrete projects are meant to emerge from it. That would still not be secured revenue, but it would help investors size the venture's commercial worth.

BASF at a turning point? This analysis reveals what investors need to know now.

The opposite outcome is a capital markets day that emphasises potential without describing the route to capturing it. Nemasphere would leave open how much weight to give the peak sales figure; the methanol tie-up would remain a first step rather than a basis for assuming actual proceeds. Jefferies illustrates how cautious the market can be: according to media reports, the broker kept BASF at "Underperform" with a 44-euro price target on Thursday, after the Evonik efforts ended. That says nothing about the house's view of individual projects, but it sets the contrast between a sceptical rating and the potential BASF attaches to Nemasphere.

As long as the company holds to its planned US and Brazil launch, investors retain a timing anchor. Credible interim milestones would let the project carry more weight in valuations; any slippage in the start date would push the prospect of first commercial revenue further out, and the peak sales figure alone would not offset that lost time. The 24 November event is the next fixed point for that reckoning — its value to shareholders depends on whether BASF converts announced intentions into checkable stages. If potential and intent are all that emerge, the projects will speak for possible additional revenue, but not yet for a correspondingly higher valuation.

Ad

BASF Stock: New Analysis - 21 November

Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BASF analysis...

Disclaimer...
en | DE000BASF111 | BASF | boerse | 70541577 |